Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children

Abstract

JE-CV (IMOJEV®, Sanofi Pasteur, France) is a live attenuated virus vaccine constructed by inserting coding sequences of the prM and E structural proteins of the Japanese encephalitis SA14-14-2 virus into the genome of yellow fever 17D virus. Primary immunization with JE-CV requires a single dose of the vaccine. This article reviews clinical trials of JE-CV in children aged up to 6 years conducted in countries across South-East Asia. Strong and persistent antibody responses were observed after single primary and booster doses, with 97% of children seroprotected up to five years after booster vaccination. Models of long-term antibody persistence predict a median duration of protection of approximately 30 years after a booster dose. The safety and reactogenicity profiles of JE-CV primary and booster doses are comparable to other widely used childhood vaccines.

Twenty Years of Progress Toward West Nile Virus Vaccine Development

“…Some countries administer two booster doses of SA14-14-2, while others recommend only a single dose [22]. Likewise, the chimeric IMOJEV® vaccine is also safe and effective when administered with just a single dose, though pediatric boosters are recommended [23]. The inactivated Vero-cell-derived JEV vaccines also have an excellent safety profile but require two primary doses as well as a recommended booster dose [18,22].…”

Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study

“…The safety and immunogenicity of primary vaccination with a single-dose JE-CV has been demonstrated in toddlers, children and adults in several endemic and epidemic areas (Chokephaibulkit et al, 2010;Feroldi et al, 2012Feroldi et al, , 2014Kim et al, 2014;Chotpitayasunondh et al, 2017;Huang et al, 2014). A single-dose JE-CV provides long-term protection that persists for at least 5 years in children (Chokephaibulkit et al, 2016;Kosalaraksa et al, 2016). The vaccine was initially licensed in Australia in 2010, and is now available or approved in a number of countries in South East Asia.…”

Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study

“…To control for the unmasking phenomenon and fundamental differences between vaccinated and unvaccinated individuals, 22 we selected Japanese encephalitis vaccine and tetanus, diphtheria, and acellular pertussis vaccine as comparators in the cohort analysis as they have well established safety profiles and are recommended in the same population of interest. [23][24][25] Hence, the study population comprised girls aged 11-14 years who were vaccinated against HPV, Japanese encephalitis, and tetanus, diphtheria, and acellular pertussis in 2017. We excluded girls who were immunised with both bivalent and quadrivalent HPV vaccines in 2017, as well as those with a diagnosis of malignancy or congenital or neonatal disease (congenital iodine deficiency syndrome, congenital hypothyroidism, transitory neonatal hyperthyroidism, other specified diseases of the pancreas, transient neonatal thrombocytopenia, neonatal diabetes mellitus, cerebral palsy, and type 1 diabetes mellitus) before the first date of vaccination.…”